Cover Image
市場調查報告書

化療誘發性嗜中性白血球低下症:開發平台分析

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 245982
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性嗜中性白血球低下症:開發平台分析 Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 120 Pages
簡介

所謂化療誘發性嗜中性白血球低下症是癌症治療最常見的副作用。常見的症狀有重度疲勞、虛弱、焦慮症、能量不足、呼吸急促、頭痛、臉色極差、心搏過速、胸口疼痛、暈眩、腹痛等。致病危險因子有年齡、併發症等。

本報告提供化療誘發性嗜中性白血球低下症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

化療誘發性嗜中性白血球低下症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Apotex Inc.
  • Biogenomics Limited
  • Bolder Biotechnology, Inc.
  • Cellerant Therapeutics, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Cinfa Biotech S.L.
  • Dr. Reddy's Laboratories Limited
  • Generon (Shanghai) Corporation Ltd.
  • Genexine, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Myelo Therapeutics GmbH
  • Octapharma AG
  • Pfenex Inc.
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Reliance Life Sciences Pvt. Ltd.
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • UAB Profarma
  • USV Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BBT-007
  • BBT-015
  • BBT-018
  • 化療誘發性嗜中性白血球低下症細胞療法
  • EC-18
  • eflapegrastim
  • F-627
  • filgrastim
  • GW-003
  • GXG-3
  • HSA-GCSF
  • Myelo-001
  • pegfilgrastim
  • romyelocel-L
  • TXA-302
  • WBI-2100
  • 開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9573IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape.

Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 4, 2, 5, 6, 9, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chemotherapy Induced Neutropenia - Overview
    • Chemotherapy Induced Neutropenia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Chemotherapy Induced Neutropenia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development
    • BeyondSpring Pharmaceuticals Inc
    • Biocon Ltd
    • Bolder Biotechnology Inc
    • Cellerant Therapeutics Inc
    • Chong Kun Dang Pharmaceutical Corp
    • Cinfa Biotech SL
    • Dr. Reddy's Laboratories Ltd
    • Gene Techno Science Co Ltd
    • Generon (Shanghai) Corp Ltd
    • Genexine Inc
    • GlycoMimetics Inc
    • Hanmi Pharmaceuticals Co Ltd
    • Intas Pharmaceuticals Ltd
    • Lupin Ltd
    • Mycenax Biotech Inc
    • Myelo Therapeutics GmbH
    • Nohla Therapeutics Inc
    • Octapharma AG
    • Pangen Biotech Inc.
    • Pfenex Inc
    • Pfizer Inc
    • Reliance Life Sciences Pvt Ltd
    • Richter Gedeon Nyrt
    • Sandoz International GmbH
    • USV Pvt Ltd
  • Chemotherapy Induced Neutropenia - Drug Profiles
    • BBT-007 - Drug Profile
    • BBT-015 - Drug Profile
    • BBT-018 - Drug Profile
    • Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
    • Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
    • EC-18 - Drug Profile
    • eflapegrastim - Drug Profile
    • F-627 - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • GMI-1271 - Drug Profile
    • GW-003 - Drug Profile
    • HSA-GCSF - Drug Profile
    • lenograstim - Drug Profile
    • Myelo-001 - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • plinabulin - Drug Profile
    • romyelocel-L - Drug Profile
    • WBI-2100 - Drug Profile
    • YPEG-Filgrastim - Drug Profile
  • Chemotherapy Induced Neutropenia - Dormant Projects
  • Chemotherapy Induced Neutropenia - Discontinued Products
  • Chemotherapy Induced Neutropenia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Biocon Ltd, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology Inc, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics Inc, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech SL, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co Ltd, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corp Ltd, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Genexine Inc, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by GlycoMimetics Inc, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Intas Pharmaceuticals Ltd, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Lupin Ltd, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Nohla Therapeutics Inc, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Pangen Biotech Inc., H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H2 2017
  • Chemotherapy Induced Neutropenia - Pipeline by USV Pvt Ltd, H2 2017
  • Chemotherapy Induced Neutropenia - Dormant Projects, H2 2017
  • Chemotherapy Induced Neutropenia - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Chemotherapy Induced Neutropenia - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top